Black Diamond Therapeutics, Inc. (BDTX)

NASDAQ: BDTX · IEX Real-Time Price · USD
1.86
-0.12 (-5.84%)
May 18, 2022 12:50 PM EDT - Market open
Market Cap67.32M
Revenue (ttm)n/a
Net Income (ttm)-120.80M
Shares Out36.29M
EPS (ttm)-3.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,144
Open1.96
Previous Close1.97
Day's Range1.85 - 1.96
52-Week Range1.77 - 24.07
Beta1.54
AnalystsBuy
Price Target8.42 (+353.9%)
Earnings DateMay 13, 2022

About BDTX

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance...

IndustryBiotechnology
IPO DateJan 30, 2020
Employees86
Stock ExchangeNASDAQ
Ticker SymbolBDTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is 8.42, which is an increase of 353.91% from the latest price.

Price Target
$8.42
(353.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterK...

1 day ago - GlobeNewsWire

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based...

- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine -

5 days ago - GlobeNewsWire

Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterK...

6 days ago - GlobeNewsWire

Executives Buy Around $1.6M Of 4 Penny Stocks

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.

Other symbols:HMTV
2 weeks ago - Benzinga

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

– Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts –

3 weeks ago - GlobeNewsWire

Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

1 month ago - GlobeNewsWire

Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

1 month ago - GlobeNewsWire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

2 months ago - GlobeNewsWire

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

2 months ago - GlobeNewsWire

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

2 months ago - GlobeNewsWire

Hot Penny Stocks to Add to Your Mid-January Watchlist

Are these penny stocks worth buying in 2022? The post Hot Penny Stocks to Add to Your Mid-January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:PHUNRIG
4 months ago - PennyStocks

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR fo...

CAMBRIDGE, Mass. and NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

4 months ago - GlobeNewsWire

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

CAMBRIDGE, Mass. and NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

4 months ago - GlobeNewsWire

Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

4 months ago - GlobeNewsWire

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

6 months ago - GlobeNewsWire

Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

6 months ago - GlobeNewsWire

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC...

CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master...

7 months ago - GlobeNewsWire

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC I...

CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

7 months ago - GlobeNewsWire

Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste...

7 months ago - GlobeNewsWire

Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform

Strategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology

7 months ago - GlobeNewsWire

Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

9 months ago - GlobeNewsWire

Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

9 months ago - GlobeNewsWire

Black Diamond Therapeutics Stock Plunges On Safety Signals In Solid Tumor Study Of BDTX-189

Black Diamond Therapeutics Inc (NASDAQ: BDTX) reported initial data from the Phase 1 dose-escalation portion of the Phase 1/2 MasterKey-01 trial evaluating BDTX-189 in patients with advanced solid tumor...

11 months ago - Benzinga

Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Adv...

Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions

11 months ago - GlobeNewsWire